Search Results - "Heumann, Thatcher"

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report.

Authors: Munjapara, Vasu Heumann, Thatcher Schreck, Karisa C. et al.

Source: Case Reports in Oncology. 2022, Vol. 15 Issue 3, p909-917. 9p.

Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma.

Authors: Thummalapalli, Rohit Heumann, Thatcher Stein, Julie et al.

Source: Case Reports in Oncology. 2020, Vol. 13 Issue 2, p508-514. 7p.

Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.

Authors: Eghbali, Shabnam Heumann, Thatcher Ross

Source: Cancers. Jan2025, Vol. 17 Issue 2, p236. 28p.

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.

Authors: Heumann, Thatcher R. Baretti, Marina Sugar, Elizabeth A. et al.

Source: Clinical Epigenetics. 12/3/2022, Vol. 14 Issue 1, p1-11. 11p.

End‐Of‐Life Outcomes and Healthcare Utilization for Patients With Hepatocellular Carcinoma Who Received Immune Checkpoint Inhibition.

Authors: Wheless, Margaret C. Uhelski, Anna‐Carson R. Cimino, Sarah K. et al.

Source: Cancer Medicine. Oct2025, Vol. 14 Issue 19, p1-9. 9p.

CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation.

Authors: Danish, Hasan Heumann, Thatcher Bradley, Kyle et al.

Source: Dermatology & Therapy. Jun2016, Vol. 6 Issue 2, p251-263. 13p.

Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.

Authors: Lo, Justin H. Agarwal, Rajiv Goff, Laura W. et al.

Source: Cancers. Jul2023, Vol. 15 Issue 13, p3312. 26p.